Evidence map›Paper›PMID 40571854›Full record

ArticleInsights into imaging2025

A machine learning model integrating clinical-radiomics-deep learning features accurately predicts postoperative recurrence and metastasis of primary gastrointestinal stromal tumors.

WenJie Xie, Zhen Zhang, Zhao Sun, XiaoChen Wan, JieHan Li, JianWu Jiang, Qi Liu, Ge Yang, Yang Fu

Abstract read
In one paragraph

Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

WenJie XieDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhen ZhangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhao SunDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
XiaoChen WanDepartment of Gastrointestinal Surgery, Henan Cancer Hospital, Zhengzhou, China.
JieHan LiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
JianWu JiangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qi LiuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ge YangOphthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. younglioness@163.com.
Yang FuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. fuyang@zzu.edu.cn.ORCID http://orcid.org/0000-0002-8221-3354

Funding

First Affiliated Hospital of Zhengzhou University QNCXTD2023022Health Commission of Henan Province Nos. YXKC2020029/2020054Health Commission of Henan Province SBGJ2020002041Natural Science Foundation of Henan Province No. 212300410075Training Program for Young Backbone Teachers of colleges and universities in Henan Province 2019GGJS024
6 · The paper itself

Abstract

objectivesPost-surgical prediction of recurrence or metastasis for primary gastrointestinal stromal tumors (GISTs) remains challenging. We aim to develop individualized clinical follow-up strategies for primary GIST patients, such as shortening follow-up time or extending drug administration based on the clinical deep learning radiomics model (CDLRM).

methodsThe clinical information on primary GISTs was collected from two independent centers. Postoperative recurrence or metastasis in GIST patients was defined as the endpoint of the study. A total of nine machine learning models were established based on the selected features. The performance of the models was assessed by calculating the area under the curve (AUC). The CDLRM with the best predictive performance was constructed. Decision curve analysis (DCA) and calibration curves were analyzed separately. Ultimately, our model was applied to the high-potential malignant group vs the low-malignant-potential group. The optimal clinical application scenarios of the model were further explored by comparing the DCA performance of the two subgroups.

resultsA total of 526 patients, 260 men and 266 women, with a mean age of 62 years, were enrolled in the study. CDLRM performed excellently with AUC values of 0.999, 0.963, and 0.995 for the training, external validation, and aggregated sets, respectively. The calibration curve indicated that CDLRM was in good agreement between predicted and observed probabilities in the validation cohort. The results of DCA's performance in different subgroups show that it was more clinically valuable in populations with high malignant potential.

conclusionCDLRM could help the development of personalized treatment and improved follow-up of patients with a high probability of recurrence or metastasis in the future. CRITICAL RELEVANCE STATEMENT: This model utilizes imaging features extracted from CT scans (including radiomic features and deep features) and clinical data to accurately predict postoperative recurrence and metastasis in patients with primary GISTs, which has a certain auxiliary role in clinical decision-making. KEY POINTS: We developed and validated a model to predict recurrence or metastasis in patients taking oral imatinib after GIST. We demonstrate that CT image features were associated with recurrence or metastases. The model had good predictive performance and clinical benefit.

Indexed as

Deep learningGastrointestinal stromal tumorsMachine learningRadiomicsRecurrence or metastasis

Identifiers

PMID40571854
PMCPMC12202268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.